Search results
Results from the WOW.Com Content Network
Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. [6] It is primarily used to manage the symptoms of Parkinson's disease, but it does not slow down the disease or stop it from getting worse. [6]
Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa.This property is significant in that it allows a greater proportion of administered levodopa to cross the blood–brain barrier for central nervous system effect, instead of being peripherally metabolised into substances unable to cross said barrier.
Orphenadrine (sold under many brand names) [1] is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine.It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs.
Trihexyphenidyl (THP, benzhexol, trihex, marketed as Artane and others) is an antispasmodic drug used to treat stiffness, tremors, spasms, and poor muscle control. It is an agent of the antimuscarinic class and is often used in management of Parkinson's disease.
Selegiline, also known as L-deprenyl and sold under the brand names Eldepryl, Zelapar, and Emsam among others, is a medication which is used in the treatment of Parkinson's disease and major depressive disorder.
Levodropropizine is a cough suppressant.It is the levo isomer of dropropizine.It acts as a peripheral antitussive, with no action in the central nervous system. [1] It does not cause side effects such as constipation or respiratory depression which can be produced by opioid antitussives such as codeine and its derivatives.
For example, in clinical trials of sildenafil, 28 percent of men reported headache (by far the most common side effect) at a dosage of 100mg, compared to just 16 percent of men who used 25mg and ...
The subject expert committee of CDSCO has recommended the grant of permission for manufacturing and marketing of Desidustat 25 mg and 50 mg tablets in India, based on some conditions related to package insert, phase 4 protocols, prescription details, and GCP. [3] Clinical trials on desidustat have been done in India and Australia. [4]